China NMPA Inspection - Lanzhou Ximai Memory Alloy Co., Ltd. - August 10, 2017

On August 10, 2017, the State Administration of Drug Administration (SDA) issued Announcement No. 129, targeting Lanzhou Ximai Memory Alloy Co., Ltd. This official directive mandated the immediate suspension of the company's production operations and required thorough rectification. While the specific details regarding the inspection dates and the exact nature of the violations are not provided within this announcement title, the regulatory action unequivocally signals non-compliance with established manufacturing or quality management regulations. Such measures are typically enforced following an inspection that uncovers deficiencies serious enough to warrant a halt in production. The State Administration of Drug Administration, acting under China's comprehensive regulatory framework for drugs and medical devices, is responsible for safeguarding public health through strict oversight of manufacturing practices. Consequently, Lanzhou Ximai Memory Alloy Co., Ltd. is compelled to implement corrective actions to address all identified issues and achieve full compliance before it can apply to resume its manufacturing activities. This ensures that future products meet the required safety and quality standards.